Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2824765 | 0.80 | CA1 (0.34) | CA1L3MBTL1 | |
| SCHEMBL13969227 | 0.77 | CA1 (0.32) | CA1L3MBTL1 | |
| SCHEMBL27726679 | 0.77 | L3MBTL1 (0.34) | CA1L3MBTL1 | |
| SCHEMBL7170151 | 0.77 | TSHR (0.38) | — | |
| SCHEMBL551928 | 0.75 | TSHR (0.38) | — | |
| SCHEMBL28773718 | 0.74 | PTPN1 (0.34) | CA1 | |
| SCHEMBL28077465 | 0.74 | MEN1 (0.46) | L3MBTL1 | |
| SCHEMBL13969223 | 0.73 | CA1 (0.36) | CA1L3MBTL1 | |
| SCHEMBL11102231 | 0.73 | ALDH1A1 (0.42) | — | |
| SCHEMBL7783900 | 0.72 | CA1 (0.39) | CA1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE41289-E1 | Ultrashort acting hypnotic barbiturates | ARYX THERAPEUTICS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7041673-B2 | High speed metabolism; antiepileptic agents; anesthetics; central nervous system disorders; anxiolytic agents | ARYX THERAPEUTICS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-20040167143-A1 | Ultrashort acting hypnotic barbiturates | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2004-08-26 | — | — | US | disclosed |
| US-6683086-B2 | DERIVATIVES OF BARBITURIC AND THIOBARBITURIC ACIDS; RAPIDLY METABOLIZED BY BLOOD AND TISSUE ENZYMES TO FORM POLAR METABOLITES WITH NO HYPNOTIC ACTIVITY AND WHICH ARE RAPIDLY ELIMINATED | ARYX THERAPEUTICS | 2004-01-27 | — | — | US | disclosed |
| US-20030100575-A1 | Ultrashort acting hypnotic barbiturates | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2003-05-29 | — | — | US | disclosed |
| EP-1276728-A2 | ULTRASHORT ACTING HYPNOTIC BARBITURATES | ARYx Therapeutics (US) | 2003-01-22 | — | — | EP | disclosed |
| US-6387914-B2 | PROVIDING SEDATIVE-HYPNOTIC TREATMENT BY ADMINISTERING BARBITURATE DERIVATIVE COMPOUND | ARYX THERAPEUTICS | 2002-05-14 | — | — | US | disclosed |
| US-20020013330-A1 | Ultrashort acting hypnotic barbiturates | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2002-01-31 | — | — | US | disclosed |
| WO-2001081319-A2 | ULTRASHORT ACTING HYPNOTIC BARBITURATES | ARYX THERAPEUTICS (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167143-A1 | Ultrashort acting hypnotic barbiturates | GABRR1, GABRA1, GABRR2 | CA1 137/4885L3MBTL1 633/4885 |
| US-20030100575-A1 | Ultrashort acting hypnotic barbiturates | GABRR1, GABRA1, GABRR2 | CA1 137/4885L3MBTL1 633/4885 |
| US-20020013330-A1 | Ultrashort acting hypnotic barbiturates | GABRR1, GABRA1, GABRR2 | CA1 137/4885L3MBTL1 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.